1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Platelet Rich Plasma Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Platelet Rich Plasma Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Pricing Analysis
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Platelet Rich Plasma Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Pure-PRP
6.3.2. Leukocyte-rich PRP
6.3.3. Pure-PRF
6.4. Market Attractiveness Analysis, by Type
7. Global Platelet Rich Plasma Market Analysis and Forecast, by Origin
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Origin, 2017–2031
7.3.1. Autologous
7.3.2. Allogeneic
7.3.3. Homologous
7.4. Market Attractiveness Analysis, by Origin
8. Global Platelet Rich Plasma Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Orthopedic Surgery
8.3.2. Cosmetic Surgery
8.3.3. General Surgery
8.3.4. Neurosurgery
8.3.5. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Platelet Rich Plasma Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Global Platelet Rich Plasma Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Pure-PRP
10.2.2. Leukocyte-rich PRP
10.2.3. Pure-PRF
10.3. Market Value Forecast, by Origin, 2017–2031
10.3.1. Autologous
10.3.2. Allogeneic
10.3.3. Homologous
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Orthopedic Surgery
10.4.2. Cosmetic Surgery
10.4.3. General Surgery
10.4.4. Neurosurgery
10.4.5. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Origin
10.6.3. By Application
10.6.4. By Country
11. Europe Global Platelet Rich Plasma Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Pure-PRP
11.2.2. Leukocyte-rich PRP
11.2.3. Pure-PRF
11.3. Market Value Forecast, by Origin, 2017–2031
11.3.1. Autologous
11.3.2. Allogeneic
11.3.3. Homologous
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Orthopedic Surgery
11.4.2. Cosmetic Surgery
11.4.3. General Surgery
11.4.4. Neurosurgery
11.4.5. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Origin
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Global Platelet Rich Plasma Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Pure-PRP
12.2.2. Leukocyte-rich PRP
12.2.3. Pure-PRF
12.3. Market Value Forecast, by Origin, 2017–2031
12.3.1. Autologous
12.3.2. Allogeneic
12.3.3. Homologous
12.4. Market Value Forecast By Application, 2017–2031
12.4.1. Orthopedic Surgery
12.4.2. Cosmetic Surgery
12.4.3. General Surgery
12.4.4. Neurosurgery
12.4.5. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Origin
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Latin America Global Platelet Rich Plasma Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Pure-PRP
13.2.2. Leukocyte-rich PRP
13.2.3. Pure-PRF
13.3. Market Value Forecast, by Origin, 2017–2031
13.3.1. Autologous
13.3.2. Allogeneic
13.3.3. Homologous
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Orthopedic Surgery
13.4.2. Cosmetic Surgery
13.4.3. General Surgery
13.4.4. Neurosurgery
13.4.5. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Origin
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Middle East & Africa Global Platelet Rich Plasma Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Pure-PRP
14.2.2. Leukocyte-rich PRP
14.2.3. Pure-PRF
14.3. Market Value Forecast, by Origin, 2017–2031
14.3.1. Autologous
14.3.2. Allogeneic
14.3.3. Homologous
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Orthopedic Surgery
14.4.2. Cosmetic Surgery
14.4.3. General Surgery
14.4.4. Neurosurgery
14.4.5. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Origin
14.6.3. By Application
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Zimmer Biomet Holdings, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. AdiStem Ltd.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. ISTO Biologics
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. ThermoGenesis Holdings, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Stryker Corporation
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Exactech, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. EmCyte Corporation
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. Regen Lab
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. Arthrex, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
15.2.10. TERUMO BCT, INC. (Terumo Corporation)
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Strategic Overview
15.2.10.5. SWOT Analysis
15.2.11. DePuy Synthes Companies (Johnson & Johnson)
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis
15.2.12. APEX Biologix, LLC
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Financial Overview
15.2.12.3. Product Portfolio
15.2.12.4. Strategic Overview
15.2.12.5. SWOT Analysis